SC1 Identification & Characterization of Cancer Stem Cells
This course will provide an overview of the unique challenges of isolation and characterization of cancer stem cells, including identification and validation of surface markers, isolating CSCs from tumor cell populations and adult stem cells, and establishing, maintaining and working with cell lines.
Jaspal Khillan, Ph.D., Associate Professor, Microbiology and Molecular Genetics, University of Pittsburgh
Leslie Crews Robertson, Ph.D., Jamieson Laboratory, Sanford Consortium for Regenerative Medicine & Moores UC San Diego Cancer Center
Jennie Mather, Senior Vice President, Stem Cell Technologies, Macrogenics, Inc.
Kristen M. Smith, Ph.D., Scientist II, Bionomics, Inc.
SC2 Commercialization Boot Camp: Manual for Success in the Molecular Diagnostics Marketplace
This workshop will define the priority checklist for executing a successful strategy and operational plan for commercializing molecular diagnostics. It will examine the process of bringing a product to market based on data driven case histories. Financial resources needed to execute the project plan will be measured in the current climate. Participants will receive an operational roadmap document that details key requirements for advancing molecular diagnostics through product development. This course will leverage the instructors’ years of accumulated experience spanning financial, technical and scientific acumen, as well as overcoming roadblocks on the path to commercial success.
Maureen Cronin, Ph.D., Executive Director, Strategic Information Management, Celgene Corporation
Harry Glorikian, Managing Director, Scientia Advisors
SC3 NGS Data and the Cloud - Detailed Agenda
This course will compare cloud computing to internal infrastructure as well as give a cost-benefit analysis of cloud computing by platform type and application type. Data management and integration will also be discussed.
Adam Kraut, Scientific Consultant, BioTeam, Inc.
Jacob Glanville, Scientific Director, Distributed Bio
SC4 Best Practices in Personalized and Translational Medicine - Detailed Agenda
Award-winning speakers from the 2012 Bio-IT World Best Practices competition will give attendees an in-depth look at cutting edge solutions and techniques for advancing translational medicine research. Going beyond the original entries, Best Practices winners will give updates, answer questions, and share the secrets to their programs’ success. This course provides you with an opportunity to “go behind the curtain” and see why our judges chose these entries as the best of the best.
Kevin Davies, Ph.D., Chief Editor, Bio-IT World
Elizabeth Worthey, Ph.D., Assistant Professor, Human and Molecular Genetics Center, Department of Pediatrics, Medical College of Wisconsin
Martin G. Reese, President and CEO, Omicia, Inc.
Xing Xu, Ph.D., Director, Cloud Computing Product, BGI Americas Corporation
Pek Yee Lum, VP Life Sciences, Ayasdi, Inc.
SC5 Latest Advances in Molecular Pathology - Detailed Agenda
This course is designed to educate practicing pathologists on the current molecular diagnostics technologies, including an introduction to molecular pathology methods, diagnostics of cancer, and microarray Comparative Genomic Hybridization (CGH). The course is created in collaboration between Cambridge Healthtech Institute and the College of American Pathologists.
Iris Schrijver, M.D., Associate Professor of Pathology and Pediatrics; Director, Molecular Pathology Laboratory, Stanford University Medical Center, Lucile Packard Children’s Hospital
Athena Cherry, Ph.D., Director, Cytogenetics Laboratory; Professor, Pathology and Pediatrics, Stanford Comprehensive Cancer Center
Madhuri Hegde, Ph.D., FACMG, Associate Professor, Senior Director, Emory Genetics Laboratory, Department of Human Genetics, Emory University School of Medicine
SC6 Regulatory Approval of a Therapeutic & Companion Diagnostic: Nuts & Bolts
This course will cover some important topics related to regulatory compliance in companion diagnostics such as US requirements and processes, US government oversight of diagnostics, diagnostic clearance and approval pathways, co-development process & timelines, integration of Rx and Dx development plans, navigating the development process, co-development examples and lessons learned, approval path for devices ex-US and more.
Maham Ansari, MS, RAC, Senior Associate, Regulatory Affairs, Strategic Regulatory Services, OptumInsight, Inc. (UnitedHealth Group)
Pamela L. Swatkowski, Director, Regulatory Affairs, Abbott Molecular, Inc.
SC7 PCR Part I: qPCR in Molecular Diagnostics - Detailed Agenda
This course will cover aspects of incorporating qPCR into standard diagnosis including the challenges involved, an overview of the technology available, and next steps.
Fred Russell Kramer, Ph.D., Professor, Department of Microbiology and Molecular Genetics, Public Health Research Institute, New Jersey Medical School
Steve Miller, M.D., Ph.D., Director, UCSF Clinical Microbiology Laboratory
G. Mike Makrigiorgos, Ph.D., Director, Biophysics Laboratory and Medical Physics Division, Dana Farber Cancer Institute, Harvard Medical School
SC8 Data Visualization in Biology: From the Basics to Big Data
This course will cover essential data visualization principles, the most common visualization methods for genomics data and tools that implement them, as well as solutions for visualizing big data. You will learn how to choose appropriate methods for your visualization problems and how to address the visualization challenges of large and complex data sets that are now common in biology.
Nils Gehlenborg, Ph.D., Research Associate, Center for Biomedical Informatics, Harvard Medical School
SC10 PCR Part II: Digital PCR Applications and Advances - Detailed Agenda
This course will provide an introduction to digital PCR while showcasing novel technologies for research, innovative amplification techniques, and strategies for solving common research bottlenecks.
Bruce K. Gale, Ph.D., Associate Professor and Director, State of Utah Center of Excellence for Biomedical Microfluidics, Department of Mechanical Engineering, University of Utah
Frank Diehl, Ph.D., Managing Director, Chief Scientific Officer, Inostics GmbH
Darren R. Link, Ph.D., Co-Founder and Vice President, R&D, Raindance Technologies, Inc.
SC11 Sample Prep and Biorepositories for Cancer Research - Detailed Agenda
This course will educate the participants on the basics of biorepositories for cancer research.It will cover the use of different types of cancer specimens, including liquid and tissue samples.Standard operating procedures for collecting, banking and distributing clinical samples will be reviewed.
Irina A. Lubensky, M.D., Chief, Resources Development Branch, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis NCI, NIH
Christopher A. Moskaluk, M.D., Ph.D., Walter Reed Professor and Chair of Pathology, University of Virginia Health System
Nilsa C. Ramirez, M.D., Director, Surgical Pathology, Department of Pathology and Laboratory Medicine, Nationwide Children’s Hospital; Medical Director, Biopathology Center, Co-Investigator and Lead Pathologist, TCGA BCR, The Research Institute at Nationwide Children’s Hospital
Elisabeth Paietta, Ph.D., Professor of Medicine, Albert Einstein College of Medicine, Director, ECOG Leukemia Translational Research Laboratory and Leukemia Tissue Bank, Montefiore Medical Center-North Division
SC12 Next-Generation Sequencing in Molecular Pathology: Challenges and Applications - Detailed Agenda
The focus of this short course will be on understanding the use of NGS in clinical diagnosis, practical implementation of NGS in clinical laboratories and analysis of large data sets by using bioinformatics tools to parse and interpret data in relation to the clinical phenotype. The course is created in collaboration between Cambridge Healthtech Institute and the College of American Pathologists.
Wayne Grody, M.D., Ph.D., FCAP, FACMG, Professor, Departments of Pathology & Laboratory Medicine, Pediatrics, and Human Genetics, University of California Los Angeles School of Medicine
Karl Voelkerding, M.D., Associate Professor, Pathology, University of Utah; Medical Director, Advanced Technology & Bioinformatics, ARUP Laboratories
Nazneen Aziz, Ph.D., Director, Molecular Medicine, College of American Pathologists
SC13 Strategies for Companion Diagnostics Development
Global IVD leaders and experienced consultants will present lessons learned in the development of companion diagnostics, strategies for companion diagnostic development and commercialization, and design of drug clinical trials incorporating a companion diagnostic.
Theo McCormick, Director, RxDx Services, Management Science Associates, Inc.
John F. Beeler, Ph.D., Director, Theranostics & Business Development, bioMerieux
Sabah Malek, Senior Regulatory Scientist, IVD/Medical Devices, Voisin Consulting Life Sciences
Cecilia Schott, Pharm.D., M.B.A., Executive Business Development Director, Personalized Healthcare, AstraZeneca
SC14 Patient-Derived Cancer Tissue Xenograft Models
Most drugs fail in late stages of clinical development that address drug efficacy. This is particularly true for oncology therapeutics where the major attrition occurs from Phase II onwards due to limited-to-no beneficial clinical outcomes. It is extremely important therefore to implement better predictive and more clinically informative pre-clinical models, as well capable of capturing individualized aspects of disease clinical course. New generation of patient-derived cancer tissue xenograft models (pdx) show high genetic heterogeneity and mimic closely both histopathologic and molecular aspects of human cancer biology.
This course will cover:
•Cutting edge xenografting methods
•Legal and technical issues of handling human cancer tissue
•Value and the limitations of xenograft models
•Case studies of preclinical trials using patient derived xenograft models
Neal Goodwin, Ph.D., Director, Research and Development, in vivo Pharmacology Services, The Jackson Laboratory
Byron C. Hann, M.D., Ph.D., Associate Researcher, Manager of Pre-Clinical Therapeutics Core, UCSF Helen Diller Family Comprehensive Cancer Center
Regina Gandour-Edwards, M.D., Director, Cancer Center Biorepository, Department of Pathology and Laboratory Medicine, UC Davis
SC16 Microfluidics Technology and Market Trends - Detailed Agenda
In recent years, microfluidic and micro/nano technologies have transformed research and experienced impressive market growth allowing novel applications and market avenues. This course will provide an overview of the microfluidic market for in vitro diagnostics as well as keys to market entry and future perspectives.
Richard Selden, M.D., Ph.D., CEO, NetBio
Ali Tinazli, Director, Business Development & Sales, Sony DADC
Leanna Levine, Ph.D., President and CEO, ALine, Inc.
Andrew Dallas, President & CTO, Full Spectrum Software, Inc.
SC17 Open Cloud & Data Science: Understanding Key Concepts to Collaborate and Build Solutions for the Patient - Detailed Agenda
This course will enable participants to learn open cloud concepts and applications around data intensive science, broad data, and SMART Architecture to enable substitutable medical applications. Case studies will be presented.
Jason Stowe, CEO and Founder, Cycle Computing
Peter Wyngaard, Chief Technology Officer, Compendia Bioscience – now part of Life Technologies
Joshua Mandel, M.D., S.B. Research Faculty, Harvard Medical School/Children’s Hospital Informatics Program; Lead Architect for the SMART project, Harvard Medical School/Office of the National Coordinator for Health IT
*Separate registration required for a la carte pricing.